Shanghai Serum Bio-Technology Co., Ltd. Class A
SSSE:68816330.63
CNY
-1.51
(-4.70%)
ISIN
CNE1000059X8
Return %
Stock
S&P 500
1Y
31.18
14.20
3Y
60.45
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Tie Jiong Fan
- Full Time Employees
- 330
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Shanghai China
- IPO Date
- Mar 11, 2022
- Website
- serum-china.com.cn
- Similar Companies
- Business
- Shanghai Serum Bio-Technology Co., Ltd. is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of specialized antitoxins, antivenoms, and antiserum biologic therapeutics for critical emergency medicine and biosafety applications. Founded in 1999 and headquartered in Shanghai, China, the company operates as the sole licensed manufacturer of snake antivenoms in China, maintaining an integrated business structure spanning raw plasma sourcing, immunoglobulin processing, formulation, and commercial distribution. The company organizes its principal operations into three core biopharmaceutical product categories: Snake Antivenoms, Tetanus Prophylaxis and Therapeutics, and Rabies Passive Immunization. Its primary commercial products include monovalent snake antivenoms, consisting of Halys viper antivenom for pit viper envenomations, Deinagkistrodon acutus antivenom for five-pace viper envenomations, Naja atra antivenom for Chinese cobra envenomations, and Bungarus multicinctus antivenom for many-banded krait envenomations; equine tetanus immunoglobulin F(ab')2 formulations utilizing enzymatic cleavage and purification technologies to lower heterologous protein loads and minimize allergic reactions relative to conventional horse serum; and purified equine anti-rabies serum used for rapid post-exposure passive immunity following severe animal exposures. In addition to its core therapeutic lines, the company develops specialized in-vitro diagnostic products, including rapid snake venom detection and identification kits to aid clinical triage in emergency hospital settings. The company operates modern biopharmaceutical manufacturing facilities in Shanghai alongside a dedicated equine immunization and plasma collection base situated in Dafeng, Jiangsu Province. Its primary customer base encompasses public general and specialized hospitals, emergency medical centers, municipal and provincial disease control and prevention centers, and national and regional emergency drug reserves throughout mainland China, alongside select overseas public health stockpiles. In recent strategic and operational developments, Shanghai Serum Bio-Technology Co., Ltd. has advanced its clinical-stage pipeline, progressing clinical trials for novel emergency biologics including anti-bee venom serum and expanding research into broad-spectrum antivenom candidates and novel venom diagnostic platforms. The company has invested in the technical refinement of its F(ab')2 antibody fragment platform to enhance product purity, stability, and shelf life for emergency stockpiling. Furthermore, the company has implemented capacity expansion and facility modernization projects across its plasma processing and purification units to meet growing emergency reserve demands, while deepening collaborative relationships with public health authorities and emergency healthcare networks across the Asia-Pacific region following its listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange.